Walvax

China greenlights another domestic HPV shot

China’s National Medicinal Products Administration has approved Walvax’s bivalent HPV vaccine for the prevention of cervical cancer caused by HPV 16 and HPV 18, Chinese media sources reported last week.

The shot will compete for domestic market share against GSK, Merck, and China’s Xiamen Innovax.

Mentions:
Walvax, HPV, vaccines, regulatory, Xiamen Innovax, GSK, Merck, CNMPA
Read more
Covid-19 development round-up: February 25, 2022

The state of the fight: 

Sanofi and GSK’s vaccine candidate demonstrated 58% efficacy against symptomatic Covid-19 in Phase 3.
  Hetero Pharma’s generic version of Merck’s molnupiravir reduced the risk of hospitalization by over 65%.
  Britain and Japan pledged a combined $514 million to CEPI’s pandemic preparedness plan.   AUTHORIZED VACCINES

 
The U.S. FDA lifted its clinical hold on Bharat Biotech’s Covaxin, clearing the way for the inactivated vaccine to…

Mentions:
Covid-19, vaccines, drugs, Bharat Biotech, FDA, Ocugen, Pfizer, BioNTech, CDC, Medicago, GSK, Moderna, Gamaleya Institute, CNBG, Sinopharm, EMA, CanSino, Anhui Zhifei Longcom, Sanofi, Thermo Fisher, Valneva, CEPI, AstraZeneca, Sinovac, Africa CDC, COVAX, WHO, J&J, Vir, Merck, Gilead, Shionogi, Suzhou Abogen, Walvax
Read more
Covid-19 development round-up: February 18, 2022

The state of the fight: 

Moderna applied for South African patents on its vaccine, potentially jeopardizing the work of the WHO-led mRNA vaccine “hub” operating in the country.
  WHO named five additional African countries that will receive vaccine technology from the hub.
  Laboratorios Farmacéuticos Rovi inked a 10-year mRNA vaccine manufacturing extension with Moderna.   AUTHORIZED VACCINES

                                       
Medigen’s protein subunit…

Mentions:
Covid-19, vaccines, drugs, Medigen, AstraZeneca, Biological E, Moderna, Novavax, Abogen, Walvax, Gamaleya Institute, WHO, Afrigen, Pfizer, BioNTech, COVAX, Gavi, Merck, Gilead, Roche, Shionogi
Read more
Covid-19 development round-up: February 11, 2022

The state of the fight: 

A Lilly mAb active against Omicron won a U.S. FDA emergency use nod.
  Novavax’s shot proved 80% efficacious in adolescents ages 12-17, according to a Phase 3 readout.
  Vaxxinity’s UB-612 vaccine candidate performed better against Omicron than an mRNA-based comparator jab.

 

AUTHORIZED VACCINES

 
J&J’s single-dose shot was only 53% efficacious against moderate to severe Covid-19 (28 days post-injection) in a final analysis…

Mentions:
Covid-19, vaccines, drugs, J&J, Novavax, FDA, Pfizer, BioNTech, Bharat Biotech, CNBG, Sinopharm, Gamaleya Institute, Sinovac, EMA, AstraZeneca, Walvax, Moderna, Biological E, African Union, COVAX, WHO, ACT-A, Lilly, Gilead, Merck, GSK, Vir, Regeneron, Roche, DNDi, Novartis
Read more
Covid-19 development round-up: December 3, 2021

The state of the fight: 

A slew of vaccine manufacturers announced plans to tackle the Omicron variant.
  Aspen Pharmacare and J&J neared a deal that would let the South African manufacturer market its own version of the Janssen shot.
  Gavi’s board approved the alliance’s COVAX strategy for 2022.

AUTHORIZED VACCINES  


New research on the Pfizer/BioNTech shot affirmed its efficacy in younger people and its safety in older people.
 
…

Mentions:
Covid-19, vaccines, drugs, Pfizer, BioNTech, BBIL, FDA, Moderna, Gamaleya Institute, AstraZeneca, CNBG, Sinopharm, J&J, Janssen, Sinovac, Valneva, CEPI, Finlay Institute, Inovio, Novavax, WHO, EMA, Walvax, CureVac, Gavi, COVAX, MPP, Africa CDC, Merck, Lilly, Regeneron, Roche, GSK, Vir, Pfizer
Read more
Covid-19 development round-up: November 12, 2021

The state of the fight: 

More European countries cautioned against Moderna’s vaccine for younger people over concerns about side effects.
  Generics companies are preparing to roll out their versions of Merck’s molnupiravir oral antiviral.
  Pfizer is in talks with 90 countries over supply deals for its antiviral candidate.

 

AUTHORIZED VACCINES  


France and Germany recommended against the Moderna vaccine for people under 30 over concerns about…

Mentions:
Covid-19, vaccines, drugs, Moderna, Pfizer, BioNTech, BBIL, WHO, AstraZeneca, CanSino, Finlay Institute, CNBG, Sinopharm, Sinovac, Walvax, Inovio, Valneva, Zydus Cadila, ACT-A, BMGF, COVAX, J&J, Janssen, EuBiologics, Merck, MPP, EMA, Regeneron, Roche
Read more
Covid-19 development round-up: September 17, 2021

The state of the fight: 

A U.S. regulatory committee endorsed booster doses for vulnerable people and those over age 65.
  Kenya outlined plans to start fill-finish production of Covid-19 shots in early 2022.
  An SII subsidiary scooped up a 15% stake in Biocon’s biologics unit as the companies launched a strategic alliance to produce and commercialize vaccines. Approved or authorized vaccines

 
A new substudy in The Lancet supports flexible schedules for the…

Mentions:
Covid-19, vaccines, drugs, AstraZeneca, EMA, Pfizer, BioNTech, Moderna, Novavax, Gamaleya Institute, CNBG, Sinopharm, J&J, Janssen, BioCubaFarma, Finlay Institute, FDA, WHO, SII, Bio E, Valneva, CureVac, Sinovac, Walvax, Biocon, Lilly, Regeneron, Roche, Gilead
Read more
Covid-19 development round-up: September 2, 2021

The state of the fight: 

The U.S. FDA set a September date to discuss Pfizer/BioNTech boosters while E.U. officials saw “no urgent need” for boosters in the already vaccinated.
  Recruitment started in India for a late-stage trial of Serum Institute of India’s Covovax in children, and Biological E won approval to study its Corbevax in children.
  Prehospital antiplatelet therapy (such as aspirin) was associated with significantly lower in-hospital mortality in some…
Mentions:
Covid-19, vaccines, drugs, BBIL, Bharat Biotech, Moderna, Pfizer, BioNTech, Sinovac, CNBG, Sinopharm, Walvax, CanSino, CDC, FDA, Nanogen, J&J, Biological E, SII, SK Bioscience, GSK, AstraZeneca, AVAT, COVAX, UNICEF, Lilly, Regeneron, Roche
Read more
Covid-19 development round-up: August 20, 2021

The state of the fight: 

Zydus Cadila’s three-dose, needle-free ZyCoV-D became the first authorized DNA-based Covid-19 vaccine.
  AstraZeneca’s AZD7442 long-acting antibody reduced infection risk by 77% in Phase 3.
  PAHO’s Revolving Fund will begin procuring Covid-19 vaccines for member states. Approved or authorized vaccines

 
Assessing antibody levels to predict Moderna’s effectiveness: Researchers at Seattle’s Fred Hutchinson Cancer Research Center announced…

Mentions:
Covid-19, vaccines, drugs, Moderna, Pfizer, BioNTech, AstraZeneca, EMA, Gamaleya Institute, Zydus Cadila, J&J, CNBG, Sinopharm, Sinovac, WHO, FDA, SK Bioscience, Valneva, Inovio, Walvax, BBIL, CEPI, Butantan Institute, CureVac, GSK, Pharmaniaga, PAHO, SII, Merck, Vir, Regeneron, Roche
Read more
Sirnaomics, Walvax team up for flu therapy

Maryland-based Sirnaomics announced last week that it will partner with China’s Walvax to co-develop its STP702 RNA interference-based influenza A therapy candidate.
 
Walvax will shell out $6.4 million upfront (plus additional milestone payments) for exclusive development and commercialization rights for STP702 in territories including China, Hong Kong, Macao and Taiwan, the press release said.

Mentions:
Sirnaomics, Walvax, flu, drugs
Read more
Subscribe to Walvax